NCT03241264View on ClinicalTrials.gov

A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 28, 2016

Primary Completion Date

October 21, 2016

Study Completion Date

October 21, 2016

Conditions
Fibrosis
Interventions
DRUG

ND-L02-s0201

Specified dose on specified day

Sponsors

Collaborators (1)

Nitto Denko Corporation
All Listed Sponsors
collaborator

Nitto Denko Corporation

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY